Florida Financial Advisors LLC Purchases 179 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Florida Financial Advisors LLC raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 26.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 850 shares of the company’s stock after buying an additional 179 shares during the period. Florida Financial Advisors LLC’s holdings in IDEXX Laboratories were worth $351,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in IDXX. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the third quarter worth $25,000. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories in the 4th quarter worth $30,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $31,000. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at approximately $38,000. Finally, Crews Bank & Trust bought a new stake in IDEXX Laboratories in the 4th quarter worth approximately $41,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on IDXX shares. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective on the stock. Bank of America raised their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Finally, Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $417.66 on Wednesday. The stock has a 50 day moving average price of $437.36 and a 200 day moving average price of $444.05. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm has a market capitalization of $33.85 billion, a P/E ratio of 39.14, a P/E/G ratio of 3.41 and a beta of 1.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.